Table 2.

Hazard ratio for progression-free survival (PFS) for receiving pembrolizumab versus nivolumab.

	Univariable hazard ratio (95% CI)	p value	Multivariable hazard ratio (95% CI)	p value
NSCLC
PFS	0.877 (0.645–1.192)	0.402	0.917 (0.663–1.267)	0.598
NSCLC in the first line
PFS	0.986 (0.490–1.984)	0.968	0.886 (0.641–1.224)	0.462
NSCLC receiving monotherapy in the first line
PFS	0.737 (0.233–2.336)	0.605	2.410 (0.141–41.276)	0.544
NSCLC receiving combined therapy in the first line
PFS	1.247 (0.458–3.397)	0.666	3.494 (0.904–13.507)	0.07
NSCLC in the second line
PFS	0.956 (0.675–1.352)	0.798	0.884 (0.612–1.278)	0.513
NSCLC receiving monotherapy in the second line
PFS	0.793 (0.521–1.206)	0.278	0.772 (0.497–1.200)	0.25
NSCLC receiving combined therapy in the second line
PFS	2.043 (1.004–4.154)	0.049	2.396 (0.788–7.283)	0.124

CI confidence interval, NSCLC non-small cell lung cancer.